Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer: Systematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical Trials.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2022.3707
Abstract: Importance Approval by the US Food and Drug Administration of immune checkpoint inhibition (ICI) for advanced gastroesophageal cancer (aGEC) irrespective of PD-L1 status has generated controversy. Exploratory analyses from individual trials indicate a lack of… read more here.
Keywords: immune checkpoint; expression; ici; analysis ... See more keywords
Referral-to-treatment attrition and its impact on outcomes of patients with advanced gastroesophageal cancers.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.e16504
Abstract: e16504Background: Advanced gastroesophageal cancers (AGCs) are aggressive tumors. Prior research has demonstrated that patients with poor prognostic cancers are inconsistently or infrequently refer... read more here.
Keywords: impact outcomes; advanced gastroesophageal; attrition impact; referral treatment ... See more keywords
Real-world ramucirumab and immune checkpoint inhibitor sequences in US patients with advanced gastroesophageal cancer.
Sign Up to like & getrecommendations! Published in 2023 at "Future oncology"
DOI: 10.2217/fon-2022-0604
Abstract: Aim: To describe real-world treatment sequences of ramucirumab relative to immune checkpoint inhibitors (ICIs) in patients with advanced gastroesophageal cancer. Methods: Retrospective, observational study including adult patients treated with ramucirumab (April 2014-June 2020) from a… read more here.
Keywords: gastroesophageal cancer; ramucirumab; patients advanced; advanced gastroesophageal ... See more keywords
Efficacy of PD-1/PD-L1 inhibitors in advanced gastroesophageal cancer based on characteristics: a meta-analysis.
Sign Up to like & getrecommendations! Published in 2023 at "Immunotherapy"
DOI: 10.2217/imt-2022-0305
Abstract: Objective: Evaluate the potency of anti-PD-1/PD-L1 antibodies in advanced gastroesophageal cancer patients with different clinical features. Methods: Randomized, controlled trials comparing anti-PD-1/PD-L1 antibodies with chemotherapy in individuals with gastroesophageal cancer were retrieved. Results: 15 trials involving… read more here.
Keywords: gastroesophageal cancer; efficacy inhibitors; inhibitors advanced; analysis ... See more keywords